TY - JOUR
T1 - Interim Estimates of 2024-2025 COVID-19 Vaccine Effectiveness Among Adults Aged ≥18 Years - VISION and IVY Networks, September 2024-January 2025
AU - CDC COVID-19 Vaccine Effectiveness Collaborators
AU - Link-Gelles, Ruth
AU - Chickery, Sean
AU - Webber, Alexander
AU - Ong, Toan C.
AU - Rowley, Elizabeth A.K.
AU - DeSilva, Malini B.
AU - Dascomb, Kristin
AU - Irving, Stephanie A.
AU - Klein, Nicola P.
AU - Grannis, Shaun J.
AU - Barron, Michelle A.
AU - Reese, Sarah E.
AU - McEvoy, Charlene
AU - Sheffield, Tamara
AU - Naleway, Allison L.
AU - Zerbo, Ousseny
AU - Rogerson, Colin
AU - Self, Wesley H.
AU - Zhu, Yuwei
AU - Lauring, Adam S.
AU - Martin, Emily T.
AU - Peltan, Ithan D.
AU - Ginde, Adit A.
AU - Mohr, Nicholas M.
AU - Gibbs, Kevin W.
AU - Hager, David N.
AU - Prekker, Matthew E.
AU - Mohamed, Amira
AU - Johnson, Nicholas
AU - Steingrub, Jay S.
AU - Khan, Akram
AU - Felzer, Jamie R.
AU - Duggal, Abhijit
AU - Wilson, Jennifer G.
AU - Qadir, Nida
AU - Mallow, Christopher
AU - Kwon, Jennie H.
AU - Columbus, Cristie
AU - Vaughn, Ivana A.
AU - Safdar, Basmah
AU - Mosier, Jarrod M.
AU - Harris, Estelle S.
AU - Chappell, James D.
AU - Halasa, Natasha
AU - Johnson, Cassandra
AU - Natarajan, Karthik
AU - Lewis, Nathaniel M.
AU - Ellington, Sascha
AU - Reeves, Emily L.
AU - DeCuir, Jennifer
AU - McMorrow, Meredith
AU - Paden, Clinton R.
AU - Payne, Amanda B.
AU - Dawood, Fatimah S.
AU - Surie, Diya
AU - Acidera, Joshua
AU - Marquez, Laura Aguilar
AU - Akinsete, Omobosola
AU - Ali, Harith
AU - Alor, Erika
AU - Appleton, Ike
AU - Arndorfer, Julie
AU - Arter, Olivia
AU - Ball, Sarah W.
AU - Bansal, Jaskiran
AU - Barrow, Anna
AU - Basobas, Leonard
AU - Baughman, Adrienne
AU - Blair, Paul W.
AU - Block, Lawrence
AU - Bosworth, Bryce
AU - Brazer, Noah
AU - Briceno, Genesis
AU - Bride, Daniel
AU - Brown, Samuel M.
AU - Buehrig, Sydney
AU - Bychkowski, Ashley
AU - Chandresakaran, Sukantha
AU - Chang, Steven Y.
AU - Chavez, Catia
AU - Clark, Dylan
AU - Cornelison, Sydney A.
AU - Davis, Jonathan M.
AU - Dixon, Brian E.
AU - Duszynski, Thomas J.
AU - Essien, Inih
AU - Evans, Yvette
AU - Fadel, William F.
AU - Fairfield, Cathy
AU - Feitsam, Courtney
AU - Ferguson, Samantha
AU - Fisher, Tammy
AU - Garner, Omai
AU - Gasparek, Sheila
AU - Gibbs, Heath
AU - Gonzalez, Daniela
AU - Gordon, Alexandra June
AU - Goyal, Anirudh
AU - Grijalva, Carlos G.
AU - Guthrie-Baker, Sydney
AU - Hampton, Jacob
AU - Hansen, John
AU - Haq, Ebaad
AU - Hernandez-Frausto, Adrian
AU - Hubel, Kinsley
AU - Hurutado-Rodriguez, Mariana
AU - Hypes, Cameron
AU - Jacobson, Karen B.
AU - Jouzestani, Milad Karami
AU - Koneru, Sindhuja
AU - Koppolu, Padma
AU - Krol, Olivia
AU - Lau, Lily
AU - Lumpkin, Jenna
AU - Lutrick, Karen
AU - Lwin, Cara T.
AU - Ma, Kevin
AU - Manchester, Kimberly
AU - Mariscal, Denisse
AU - Martinez, Amanda
AU - Mayer, David
AU - McBride, Rylie
AU - McDonald, David
AU - McKeown, Maile
AU - Mensah, Sachina
AU - Mohr, Nicholas
AU - Nassar, Paul
AU - O'Neil, Caroline
AU - Van Otterloo, Josh
AU - Ovchiyan, Elianora
AU - Parikh, Bijal
AU - Pena, Jose
AU - Perez, Cynthia
AU - Perez, Gabriela
AU - Pitre, Vanessa
AU - Pocius, Edvinas
AU - Rademacher, Jacob
AU - Ramesh, Mayur
AU - Ray, Caitlin
AU - Rivas, Carolina
AU - Saeed, Safa
AU - Saluja, Akshay
AU - Campbell, Elizabeth Salvagio
AU - Samuels, Carleigh
AU - Santana-Garces, Maria
AU - Shack, Tanisha
AU - Simon, Samantha
AU - Sohn, Ine
AU - Srinivasan, Vasisht
AU - Strait, Hannah
AU - Sullivan, Amy
AU - Talbot, H. Keipp
AU - Tam, Grace Kyin Ye
AU - Tirumala, Shruti
AU - Tran, Cody
AU - Tribbett, Emily
AU - Valencia, Alyssa
AU - Valesquez, Ivan
AU - Vogt, Lucy
AU - Vu, Kim
AU - Yerbic, Francesca
AU - Yigitkanli, Arda
AU - Zepeski, Anne
N1 - Publisher Copyright:
© 2025 Department of Health and Human Services, Inc. All rights reserved.
PY - 2025/2/27
Y1 - 2025/2/27
N2 - COVID-19 vaccination averted approximately 68,000 hospitalizations during the 2023-24 respiratory season. In June 2024, CDC and the Advisory Committee on Immunization Practices (ACIP) recommended that all persons aged ≥6 months receive a 2024-2025 COVID-19 vaccine, which targets Omicron JN.1 and JN.1-derived sublineages. Interim effectiveness of 2024-2025 COVID-19 vaccines was estimated against COVID-19-associated emergency department (ED) or urgent care (UC) visits during September 2024-January 2025 among adults aged ≥18 years in one CDC-funded vaccine effectiveness (VE) network, against COVID-19-associated hospitalization in immunocompetent adults aged ≥65 years in two networks, and against COVID-19-associated hospitalization among adults aged ≥65 years with immunocompromising conditions in one network. Among adults aged ≥18 years, VE against COVID-19-associated ED/UC visits was 33% (95% CI = 28%-38%) during the first 7-119 days after vaccination. Among immunocompetent adults aged ≥65 years from two CDC networks, VE estimates against COVID-19-associated hospitalization were 45% (95% CI = 36%-53%) and 46% (95% CI = 26%-60%) during the first 7-119 days after vaccination. Among adults aged ≥65 years with immunocompromising conditions in one network, VE was 40% (95% CI = 21%-54%) during the first 7-119 days after vaccination. These findings demonstrate that vaccination with a 2024-2025 COVID-19 vaccine dose provides additional protection against COVID-19-associated ED/UC encounters and hospitalizations compared with not receiving a 2024-2025 dose and support current CDC and ACIP recommendations that all persons aged ≥6 months receive a 2024-2025 COVID-19 vaccine dose.
AB - COVID-19 vaccination averted approximately 68,000 hospitalizations during the 2023-24 respiratory season. In June 2024, CDC and the Advisory Committee on Immunization Practices (ACIP) recommended that all persons aged ≥6 months receive a 2024-2025 COVID-19 vaccine, which targets Omicron JN.1 and JN.1-derived sublineages. Interim effectiveness of 2024-2025 COVID-19 vaccines was estimated against COVID-19-associated emergency department (ED) or urgent care (UC) visits during September 2024-January 2025 among adults aged ≥18 years in one CDC-funded vaccine effectiveness (VE) network, against COVID-19-associated hospitalization in immunocompetent adults aged ≥65 years in two networks, and against COVID-19-associated hospitalization among adults aged ≥65 years with immunocompromising conditions in one network. Among adults aged ≥18 years, VE against COVID-19-associated ED/UC visits was 33% (95% CI = 28%-38%) during the first 7-119 days after vaccination. Among immunocompetent adults aged ≥65 years from two CDC networks, VE estimates against COVID-19-associated hospitalization were 45% (95% CI = 36%-53%) and 46% (95% CI = 26%-60%) during the first 7-119 days after vaccination. Among adults aged ≥65 years with immunocompromising conditions in one network, VE was 40% (95% CI = 21%-54%) during the first 7-119 days after vaccination. These findings demonstrate that vaccination with a 2024-2025 COVID-19 vaccine dose provides additional protection against COVID-19-associated ED/UC encounters and hospitalizations compared with not receiving a 2024-2025 dose and support current CDC and ACIP recommendations that all persons aged ≥6 months receive a 2024-2025 COVID-19 vaccine dose.
UR - https://www.scopus.com/pages/publications/86000079931
U2 - 10.15585/mmwr.mm7406a1
DO - 10.15585/mmwr.mm7406a1
M3 - Article
C2 - 40014628
AN - SCOPUS:86000079931
SN - 0149-2195
VL - 74
SP - 73
EP - 82
JO - Morbidity and Mortality Weekly Report
JF - Morbidity and Mortality Weekly Report
IS - 6
ER -